CytomX Therapeutics, Inc. (CTMX) Market Cap & Valuation Ratios
CytomX Therapeutics, Inc. (CTMX) has a market cap of $505.5M and a price-to-sales ratio of 27.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTMXCytomX Therapeutics, Inc.Follow CTMX — free
—
Price chart with a free account
- Market cap
- 505.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| CTMX | 0.5 | — | 9.6 | — | — | -87% | -476% | -49% |
| ZVRA | 0.6 | 10.7 | 2.7 | 4.3 | 5.6% | +119% | 61% | 68% |
| DBVT | 0.6 | — | 80.2 | — | — | +29% | — | — |
| MDXG | 0.6 | 97.8 | 1.3 | 5.7 | 7.8% | -2% | 2% | 4% |
| OLMA | 0.6 | — | — | — | — | — | — | -65% |
| ACRS | 0.6 | — | 56.0 | — | -11.3% | -51% | — | -82% |
| ARVN | 0.5 | 30.4 | — | — | — | -15% | -6% | -4% |
| MNPR | 0.5 | — | — | — | -2.6% | — | — | -49% |
| NGNE | 0.5 | — | — | — | — | — | — | -76% |
| PHAT | 0.5 | — | 1.9 | — | -7.9% | +110% | -17% | — |
| RGNX | 0.4 | — | 1.9 | — | — | +12% | -94% | -194% |
| Median of these 10 | 30.4 | 2.3 | 5.0 | -2.6% | +12% | -6% | -57% |
; EV/Sales 9.6 vs. 2.3.
Growth vs. price
each dot a company · hover or tap for valuesCTMX and DBVT and OLMA and ACRS and MNPR and NGNE and PHAT and RGNX have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
CytomX Therapeutics, Inc. — questions
- What is CytomX Therapeutics, Inc.'s market cap?
- $505.5M.
- What is CytomX Therapeutics, Inc.'s price-to-sales ratio?
- 27.6.
Every figure on this page comes from CytomX Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.